#151181

Anti-CyclinB2 [X121.10]

Cat. #151181

Anti-CyclinB2 [X121.10]

Cat. #: 151181

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: Cyclin B2

Class: Monoclonal

Application: WB ; IHC ; IP ; WB

Reactivity: Xenopus laevis

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Julian Gannon

Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-CyclinB2 [X121.10]
  • Alternate name: Cyclin B2; HsT17299
  • Clone: X121.10
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Xenopus laevis
  • Host: Mouse
  • Application: WB ; IHC ; IP ; WB
  • Description: X121.1 may be used to immunoprecipitate active CDK1 complexes.
  • Immunogen: Xenopus laevis Cyclin B2
  • Isotype: IgG1
  • Myeloma used: Sp2/0-Ag14
  • Recommended controls: Xenopus laevis egg extract.

Target Details

  • Target: Cyclin B2
  • Tissue cell line specificity: Xenopus laevis egg extract.
  • Target background: Cyclins bind to and regulate the activity of the Cyclin Dependent Protein Kinases (CDKs).

Applications

  • Application: WB ; IHC ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 0.91 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Integrative module analysis of HCC gene expression landscapes
  • Li et al. 2020. Exp Ther Med. 19(3):1779-1788. PMID: 32104233.
  • Identification of the nuclear localization signal in Xenopus cyclin E and analysis of its role in replication and mitosis.
  • Activation of Xenopus eggs by the kinase inhibitor 6-DMAP suggests a differential regulation of cyclin B and p39(mos) proteolysis.